NCT05042375

A Trial of Camrelizumab Combined With Famitinib Malate in Treatment Naïve Subjects With PD-L1-Positive Recurrent or Metastatic Non-Small Cell Lung Cancer

A Randomized, Open-Label, Controlled, Multi-center Phase Ⅲ Study of Camrelizumab Combined With Famitinib Malate Versus Pembrolizumab in Treatment Naïve Subjects With PD-L1-Positive Recurrent or Metastatic Non-Small Cell Lung Cancer

• Status: Unknown
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 450 (estimated)
• Sponsor: Jiangsu HengRui Medicine Co., Ltd. · Industry
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

The study is being conducted to evaluate the efficacy, and safety of camrelizumab combined with famitinib malate vs. pembrolizumab in treatment naïve subjects with programmed death-ligand 1(PD-L1)-positive recurrent or metastatic non-small cell lung cancer (NSCLC).

Conditions

• Non-small Cell Lung Cancer

Interventions

Type	Name	Description
DRUG	camrelizumab + famitinib	Camrelizumab for injection, 200 mg; Famitinib malate capsules, 20 mg.
DRUG	pembrolizumab	pembrolizumab 200 mg.
DRUG	camrelizumab	Camrelizumab for injection, 200 mg.

Timeline

• Start date: 2022-09-08
• Primary completion: 2023-12-31
• Completion: 2025-12-31
• First posted: 2021-09-13
• Last updated: 2022-11-17

Locations

80 sites across 1 country: China